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ABSTRACT
Background and aims Cytisine, a nicotinic acetylcholine receptor partial agonist (like varenicline) found in some
plants, is a low-cost, effective smoking cessation medication that may appeal to Māori [the indigenous people of New
Zealand (NZ)]. The RAUORA trial aims to determine the effectiveness, safety and cost-effectiveness of cytisine (Tabex®)
versus varenicline (Champix®) for smoking cessation in Māori and the whānau (extended family) of Māori.
Design Pragmatic, community-based, open-label randomized non-inferiority trial. Setting Lakes District Health Board
region, NZ. Participants Daily smokers (n = 2140) who self-identify as Māori or whānau of Māori, and are: aged
≥ 18 years, motivated to quit smoking in the next 2 weeks, eligible for subsidized varenicline, able to provide verbal consent
and have daily access to a mobile phone/internet. Recruitment uses multi-media advertising. Intervention and
comparator Participants are randomized (1 : 1 ratio) to receive a prescription for 12 weeks of cytisine tablets [following
the manufacturer’s dosing regimen for 25 days, then one 1.5-mg tablet every 6 hours (two per day) until 12 weeks] or
varenicline tablets (following the manufacturer’s dosing regimen). Both groups receive brief stop-smoking advice from
the prescribing doctor and withdrawal-orientated behavioural support via community-based stop-smoking counselling
services (frequency, duration and mode of delivery tailored for participants) or a research assistant (six weekly 10–15-
minute calls). Participants are advised to reduce their smoking over the first 4 days of treatment, with day 5 as their
designated quit-date. Measurements The primary outcome is carbon monoxide-verified continuous abstinence at
6 months post-quit date. Secondary outcomes at 1, 3, 6 and 12 months post-quit date include: self-reported continuous
abstinence, 7-day point prevalence abstinence, cigarettes per day, time to (re)lapse, adverse events, treatment
adherence/compliance, treatment acceptability, nicotine withdrawal/urge to smoke and health-care utilization/health-
related quality of life. Comments This trial compares cytisine and varenicline when used by the indigenous people of
NZ and their extended family for smoking cessation.
Keywords Cytisine, effectiveness, indigenous, non-inferiority, randomized, safety trial, varenicline.
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INTRODUCTION
New Zealand (NZ) has a smoke-free 2025 goal (i.e.< 5% of
adults smoking by 2025). To achieve this goal, net smoking
cessation rates need to increase substantially, particularly
for Māori [indigenous New Zealanders who, in 2016,
comprised 14% of the NZ population [1]], who have a high
prevalence of daily smoking (33%) compared with the
general population (14%) [2]. Consequently, Māori have
high rates of smoking-related disease, contributing to the
7–8-year life-expectancy gap between Māori and non-
Māori in NZ [3,4].
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Standard smoking cessation treatment in NZ combines
behavioural support (BS) with pharmacotherapy (combi-
nation nicotine replacement therapy (NRT), bupropion or
varenicline) [5]. Varenicline, a nicotinic acetylcholine
receptor (nAChR) partial agonist, doubles the odds of
quitting, compared with placebo [6]. However, varenicline
is the most expensive smoking cessation medication (US
$474–501 for a full 12-week course) [7]. In NZ,
varenicline is available on prescription and is fully subsi-
dized by the Pharmaceutical Management Agency of NZ
(PHARMAC) under ‘special authority’ (an approval issued
by the Ministry of Health, on application by a medical
practitioner).
Cytisine is an alkaloid found in several plant species, in-
cluding the NZ kōwhai tree (Sophora tetraptera J.F.Mill.)
[8,9]. Like varenicline, cytisine is structurally similar to
nicotine and acts as a partial agonist at nAChR [10,11].
Cytisine is taken orally (1.5 mg cytisine/tablet) for 25 days,
starting with one tablet every 2 hours on days 1–3 (9 mg/
day), tapering to one tablet every 6 hours on days 21–25
(3 mg/day). Users are advised to reduce the number of cig-
arettes smoked during the first 4 days of treatment, and
quit on the fifth day. The drug has a half-life of 4.8 hours
[12], compared with 17 hours for varenicline [13]. Trial
evidence indicates that cytisine is superior to a placebo
[6,14–16] and NRT [17] for smoking cessation, with ad-
verse effects typically mild and self-limiting [6,14–17]. Ef-
fect sizes observed in a cytisine versus NRT trial [17] were
similar to those in a trial comparing varenicline to NRT
[18]. This finding, coupled with the current large market
price difference between cytisine and varenicline [7], the
low cost per quality-adjusted life-years (QALY) for cytisine
[19] and recent economic evaluations [20,21] suggests
that the two medications should be compared using a
non-inferiority trial design. However, varenicline comes
off-patent inMay 2020; if cytisine becomes marketed more
widely, the presence of an in-class competitor may exert a
downward pressure on the price of both medicines.
Cytisine’s occurrence as a ‘natural’ product could also
increase its appeal to Māori and other indigenous people,
smokers in countries where the use of herbal medicines is
widespread, and to those who do not wish to use other
cessation medication to quit smoking.
We designed a pragmatic, community-based, random-
ized, non-inferiority trial (named RAUORA—a Māori word
meaning ‘to rescue’) to evaluate the effectiveness, safety
and cost-effectiveness of cytisine versus varenicline for
smoking cessation. We hypothesize that 12 weeks’ treat-
ment with cytisine plus BS will be at least as effective as
12weeks’ treatment with varenicline plus BS at increasing
quit rates at 6 months post quit-date. A similar non-
inferiority trial, comparing 25 days’ treatment with
cytisine plus BS against 12 weeks’ treatment with
varenicline plus BS, is recruiting in Australia [22].
METHODS
Study population
The population of focus is NZ Māori and their whānauwho
smoke daily and reside in the Lakes District Health Board
(DHB) region of NZ.Whānau ofMāori means extended fam-
ily [23], and includes people who are not themselves Māori
by whakapapa (genealogy), but who live in a Māori whānau
(e.g. in a household by marriage). In the Lakes DHB region
of NZ (population 105170 in 2016/17) 35.2% of the pop-
ulation are Māori [24]. The region has a higher proportion
of smokers (18%) and Māori smokers (37%) compared
with national averages (14 and 33%, respectively) [2].
Eligibility criteria
Participants are eligible if they self-identify as Māori or
whānau of Māori, smoke daily and are motivated to quit
within the next 2 weeks are aged ≥ 18 years, can provide
verbal consent, and are eligible for subsidized varenicline
under special authority (i.e. they have tried, but failed, to
quit on at least two separate occasions using NRT, with
at least one of these attempts involving a comprehensive
cessation programme; or have tried previously to quit using
bupropion or nortriptyline; and have not used funded
varenicline in the last 12 months [25]). Participants must
also have daily access to a mobile phone with text capabil-
ity and/or e-mail, and access to the internet via computer
and/or smartphone. Only one person per household can
be enrolled into the study.
Exclusion criteria include pregnant and/or breast-
feeding women, people enrolled in another smoking cessa-
tion programme/study, current users of NRT, bupropion,
clonidine, nortriptyline, varenicline or e-cigarettes (with
or without nicotine), people who have used varenicline or
cytisine in the last 12 months and people with known
hypersensitivity to the study medications. Additional self-
reported exclusion criteria include: moderate/severe renal
impairment; treatment for active/latent tuberculosis; a
heart attack, stroke or severe angina within the last
2 weeks; uncontrolled high blood pressure (> 150 mmHg
systolic, > 100 mmHg diastolic); and/or a history of
seizures. These latter exclusions were requested by the
approving ethics committee based on precautions listed in
the cytisine product insert (Tabex®, manufactured by
SoPharma, Bulgaria; supplied for the trial by Achieve Life
Sciences) and animal studies [26,27].
Recruitment
Recruitment is through community-based advertising and
promotion by community-based smoking cessation
services and health professionals. Advertisements direct
potential participants to register via the study website
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and/or to call/text a researcher directly. Potential partici-
pants are telephoned by a research assistant, provided with
further trial information and assessed for eligibility. Verbal
consent is obtained from eligible and interested partici-
pants and baseline data are collected. Potential participants
who are ineligible are provided with brief cessation support
by the research assistant and referred to the national
Quitline, the regional community-based cessation provider,
and/or their general practitioner [GP]) [5].
Randomization: allocation concealment and sequence
generation
The computer-generated randomization sequence is pre-
pared by the study statistician in a 1 : 1 ratio using block
randomization with varying block sizes. After baseline data
are recorded, the research assistant advises the participant
to await a telephone call from the study doctor regarding
their treatment allocation. Prior to randomization, the
study doctor reviews each participant’s baseline data
(including any potential contraindications to the study
medicines), verifies that the participant is eligible for
varenicline via the special authority process and (if re-
quired) contacts the participant’s usual GP for clarification
of any medical concerns. The study doctor randomizes eli-
gible participants by computer while on the phone to them,
then writes a prescription for the allocated medication.
Blinding
The trial is open-label. All authors (except T.K. and V.P.) are
blinded to treatment allocation until after data lock and
analysis; however, four authors are unblinded when
reviewing serious adverse events (SAEs). The two medica-
tions look different and have different dosing regimens,
therefore participants cannot be blinded. The research
assistants are also unblinded, as questions related to the
allocated medication are asked at follow-up.
Interventions
Participants are randomized to receive a prescription for a
12-week course of cytisine (Tabex®) or varenicline
(Champix®). The study doctor advises participants to re-
duce their smoking during the first 4 days of treatment,
so that they are not smoking at all by the fifth day (their
designated quit date). Participants visit their preferred
pharmacy to collect their allocated medicine. The prescrip-
tion is uploaded by the study doctor to a secure website for
the pharmacist to access. Participating pharmacies
routinely stock and dispense varenicline, and are supplied
with pre-packaged cytisine for the study. All study medica-
tion is free for participants. As part of the NZ special
authority process pharmacies are required to dispense
varenicline in three instalments in the first 8 weeks: (1)
an initial 2-week starter pack plus two weeks’ mainte-
nance treatment; (2) 4 weeks’ maintenance treatment;
and (3) a further 4 weeks’ maintenance treatment. To
ensure comparability between the two arms, cytisine is
dispensed in the same manner as varenicline.
Cytisine
Participants follow the dosing regimen as recommended by
the manufacturer, namely:
• Days 1–3: one 1.5-mg tablet every 2 hours (maximum
six daily)
• Days 4–12: one 1.5-mg tablet every 2.5 hours (maxi-
mum five daily)
• Days 13–16: one 1.5-mg tablet every 3 hours (maxi-
mum four daily)
• Days 17–20: one 1.5-mg tablet every 4–5 hours
(maximum three daily)
• Days 21–25: one 1.5-mg tablet every 6 hours (maxi-
mum two daily)
To ensure comparability with the 12-week dosing
regimen of varenicline, cytisine use continues past day 25
at a maintenance dose of one 1.5-mg tablet every 6 hours
(two per day, equivalent to 3.0 mg/day) until 12 weeks.
There is no prior trial evidence of extended cytisine treat-
ment in smokers. The choice of maintenance dose was
supported by: (1) a dosing schedule of 12 weeks appears
safe based on unpublished pharmacology/toxicology
studies in rats (3–6months treatment) and dogs (6months
treatment) and (2) unpublished toxicology studies and
pharmacokinetic repeat-dose modelling undertaken by
Achieve Life Sciences (personal communication, February
2017). This evidence was presented to the NZ medicines
regulatory authority, who approved the use of the extended
dosing regimen.
Varenicline
Participants follow the dosing regimen as recommended by
the manufacturer, namely:
• Days 1–3: one 0.5-mg tablet once daily
• Days 4–7: one 0.5-mg tablet twice daily
• Days 8–week 12: one 1.0-mg tablet twice daily
Behavioural support
Participants in both groups receive standard smoking ces-
sation BS (motivational interviewing) available in NZ [5].
The study doctor delivers brief stop smoking advice imme-
diately after randomization (reflecting the advice delivered
by GPs and/or practice nurses [28]). Participants are also
offered a choice of additional smoking cessation BS: either
that offered within the community by Manaaki Ora Trust
(Tipu Ora) or that offered by the trial research assistants.
The first option reflects ‘real-world’ community-based
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stop-smoking counselling services, i.e. the frequency,
duration and mode of delivery of the support is tailored to
the participant and can include individual support offered
by telephone, text messaging and/or face-to-face, or group
counselling. The trial research assistants provide 6 weeks
of weekly BS telephone calls (each 10–15 minutes) post-
randomization. Participants who are smoking at the end
of the trial are offered further cessation support through
a service of their choice.
Baseline assessments
• Demographics: date of birth; sex; education; iwi [tribe];
connectedness to iwi (measured on a five-point Likert
scale, where one is ‘not very connected’ and five is ‘very
connected’); National Health Index number (a unique
identifier allocated to all New Zealanders at birth, that
enables data linkage with health records)
• Smoking history: age of initiation; cigarettes smoked per
day; years as a regular smoker; previous unsuccessful
quit attempts in past 12 months and method; type of
cigarettes smoked per day (e.g. roll-your-own and/or
factory-made)
• Other smoking-related information: cigarette depen-
dence (measured by the Fagerström Test of Cigarette
Dependence) [29,30]; belief in ability to quit smoking
(measured on a five-point Likert scale, where one is ‘very
low’ and five is ‘very high’); whether they live with other
smokers
• Alcohol use and abuse: measured using the Alcohol
Use Disorders Identification Test (AUDIT-C) to identify
people with hazardous drinking or active alcohol-use
disorders [31]
• Signs and symptoms of nicotine withdrawal, and urge to
smoke: measured using the Mood and Physical
Symptoms Scale (MPSS) [32]
• Concomitant medication: information about types of
medication currently used
• Health-related quality of life: measured using the NZ
EQ-5D Tariff 2 [33]
• Healthcare utilization: measured using items recom-
mended by PHARMAC [34], such as GPand nurse visits,
hospital in- and out-patient visits, prescription medica-
tion used, pharmaceutical co-payments, ambulance
transport, home and continuing care (if any)
Primary outcome
The primary outcome measure is 6-month continuous
abstinence (Russell Standard) defined as self-report of
smoking not more than 5 cigarettes from the quit date,
supported by biochemical validation [35]. A research assis-
tant will visit all participants who claim to be abstinent to
obtain an expired air-carbon monoxide (CO) reading using
a Bedfont Smokerlyzer (Bedfont Scientific Ltd, Maidstone,
UK), with a reading of ≤ 9 parts per million (p.p.m.) signify-
ing smoking abstinence [35].
Secondary outcomes
Secondary outcomemeasures (Table 1) are assessed at 1, 3
and 6 months post-quit date. Assessment at 1 month
enables comparison with existing cytisine trials, as it
represents the ‘end of treatment’ time-point for the
standard 25-day cytisine dosing regimen.
• Seven-day point prevalence: the proportion of partici-
pants that has stopped smoking, defined as self-report
of having smoked no cigarettes (not even a puff) in the
past 7 days
• Continuous (lapse-free) abstinence: the proportion of
participants that has stopped smoking, defined as self-
report of smoking not more than 5 cigarettes from the
quit date
• Time to first lapse: defined as time to first cigarette
smoked from the quit date, even a single puff
• Time to first relapse: defined as time to smoking more
than 5 cigarettes a day for three or more days in a row
• Cigarettes smoked per day, if the participant is smoking
• Signs and symptoms of nicotine withdrawal, and urge to
smoke (3 months): measured using the MPSS [32]
• Adverse events (AE): the type, severity and outcome of
self-reported AEs are collected at each follow-up call,
with AEs coded using MedDRA. In addition, at the time
of redeeming their prescription participants are provided
with a log-in card to access a web-based AE diary
(Table 2). Participants are asked to complete the diary
daily for the first 4 weeks, then weekly until 14 weeks
(i.e. for 2 weeks post-treatment). Automated texts
and/or e-mails are sent daily (for the first 4 weeks) then
weekly to prompt diary completion. Patient-initiated
electronic AE reporting systems of this nature have pre-
viously been shown to be effective [36,37]. In addition,
participants can report an AE at any time via: Facebook
instant messaging, their GP, community pharmacist
and/or the BS provider. Causality and the seriousness of
any SAEs will be assessed using the WHO Causality
Assessment Tool by three authors and the study doctor
immediately after reporting, with disagreement resolved
through discussion
• Acceptability (3 months): participants will be asked
whether or not they would recommend their allocated
treatment to another smoker, and what they liked or
disliked about using the product
• Treatment adherence and compliance: script filled; self-
reported pill counts; early stopping of allocated medica-
tion and reasons why
• Concomitant medication: other medications taken dur-
ing the course of the study
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• Other cessation methods: e.g. NRT, bupropion, clonidine,
nortriptyline, e-cigarettes, acupuncture, etc.
• Health-related quality of life (3 and 6months): measured
using the NZ EQ-5D Tariff 2 [33]
• Healthcare utilization: measured using items recom-
mended by PHARMAC [34]
All women who are pregnant at follow-up are asked to
discuss on-going smoking cessation support with their
Table 1 Details of follow-up.

















Data collection Data collection Data collection Data collection
Case report form A B R C1 C3 C6 C12
General data
Eligibility criteria X X
Verbal consent X X
Age and sex X
Education X
Iwi and connectedness to iwi X
National Health Index number X
Current medication X X X X X
Pregnancy X X X X X
Smoking information
Level of nicotine dependence X
Type of tobacco smoked X
Cigarettes smoked per day X X X X X
Age started X
Years smoked X
Previous quit attempts/method X
Chances of quitting/effectiveness X
Smoking in last seven days X X X X
Any smoking since quit date X X X X
Live with other smokers X
Time to lapse X X X X
Time to relapse X X X X
Withdrawal signs/symptoms X X




Healthcare utilization X X X X
Health-related quality of life X X X X
Follow-up details
Quit date X




Behavioural support provideda X X
Script redeemed X X
Acceptability of treatment X
Use of treatment X X
Other cessation support used X X X X
Adverse events X X X X
aBoth groups receive brief stop-smoking advice from the prescribing doctor immediately after randomization, and withdrawal-orientated behavioural support
from either community-based stop-smoking counselling services (the frequency, duration and mode of delivery is tailored for each participant) or the trial re-
search assistants (six weekly 10–15-minute telephone calls post-quit date).
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GP/lead maternity caregiver, and are withdrawn from
the trial.
Twelve-month follow-up is not possible for all partici-
pants due to the 3-year funding time-frame. However, we
estimate that two-thirds of the sample can be recruited in
time to enable the following data to be collected at
12months: 7-day point prevalence; continuous abstinence
(biochemically verified); time to lapse/relapse; cigarettes
smoked per day (if smoking); AEs.
Sample size
A sample size of 2140 (1070 in each group) confers 90%
power at the one-sided significance level of 2.5% to detect
a non-inferiority margin of 10% between the two groups
[38]. The 6-month continuous abstinence quit rate in
those who receive cytisine is assumed to be 22% [17]. A
6-month continuous abstinence quit rate of 28% was re-
ported in a varenicline trial undertaken in secondary care
[39]. However, we have chosen to be more conservative
and have assumed a 25% quit rate, given our pragmatic
design. The sample size accounts for a loss-to-follow-up at
6 months of 28%, based on a similar NZ non-inferiority
cytisine trial [17].
Data management
All data are collected and managed using REDCap [40].
The study will be monitored after 10 participants have
been randomized, at study close-out and twice during the
course of the trial. An independent Data Safety and
Monitoring Committee has been established, with clear
terms of reference.
Statistical analysis
Statistical analyses will be undertaken by a statistician
using SAS version 9.4 and R [41]. The analysis code will
be written and finalized prior to datalock. No interim anal-
yses are planned. Non-inferiority for the primary outcome
will be evaluated by observing whether the lower bound
of the two-sided 95% confidence interval (CI) for the risk
difference in quit rates between the groups is above the
non-inferiority limit of 10. The primary analyses will be
carried out on an intention-to-treat basis where people
with missing outcomes are assumed to be still smoking.
In the case that non-inferiority is evident, assessment as
to whether cytisine is superior to varenicline will be under-
taken using the same approach, but compared to a zero
difference. Non-inferiority studies should also be evaluated
against a per protocol population, defined on the basis of
compliance, protocol violations, and missing data [42,43].
Both sets of results will be considered when assessing the
study objective. Medication compliance will be defined as
having taken ≥ 80% of the required number of tablets
3 months post-quit.
Incidence rates, risk difference, relative risk and 95% CI
will be calculated for all binary outcomes, groups will be
compared using χ2 tests, and multiple logistic regression
will be conducted (if necessary) to adjust for imbalance in
covariates. The number of cigarettes per day will be
Table 2 Schedule for adverse event data collection in first 14 weeks.
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assessed using multiple linear regression adjusted for base-
line value. Symptoms of withdrawal (for abstainers) will be
assessed using repeated-measures mixed models adjusted
for baseline value. Time to lapse/relapse back to smoking
will be analysed using Kaplan–Meier curves, log-rank test
and Cox regression. AEs will be reported as the number of
participants (and percentage) with any type of AE or SAE
and incidence rate ratios. SAEs will be summarized accord-
ing to the type of event (death, life threatening, hospitaliza-
tion and other important medical event) and causality.
Secondary analyses will be conducted with cessation rates
corrected for any discordance between reported and veri-
fied cessation. Sensitivity analysis will be undertaken for
the primary outcome replacing missing outcomes with
multiple imputation if the level of missing data is deemed
high (i.e. > 20%), and also looking at different cut-offs for
the CO measurement, given lack of consensus about the
best reading to use. Pre-specified subgroup analyses will
be undertaken for the primary outcome by age, sex, educa-
tion, type of cigarettes smoked, level of nicotine depen-
dence, baseline AUDIT-C score and level of BS received,
using tests for heterogeneity.
Incremental QALYs per $1 million of total budget will
be estimated by conducting a trial-based health
economic evaluation [34]. Health resource use events
captured for each participant will be valued using unit
costs based on published NZ data (where available),
and where they are unavailable, published international
data (once its applicability to NZ’s context is thoroughly
assessed) or local estimates. The EQ-5D scores assessed
at different points in time will be transformed into QALYs
using the ‘area under the curve’ method [44]. Both
observed costs and QALYs will be subject to robust
regression analysis to account for baseline characteristics
and missing data. A sensitivity analysis will assess the
parameter uncertainty.
To estimate the costs and benefits of cytisine and
varenicline beyond the trial period, a Markov state transi-
tion model (an adapted version of a BENESCO model [20],
which has been used in several previous evaluations of this
kind [45–47]) will be used. In this model, three states are
assumed: current smokers, quitters and death. In the sim-
ulation, every year smokers and quitters may develop
smoking attributable diseases. Utility decrements are
assigned to both smoking attributable diseases and also to
being a smoker or a quitter. Trial data will populate this
model, as well as data from published sources applicable
to NZ (as above). Both costs and outcomes will be
discounted at a rate of 3.5% per annum for base case
analysis. Findings will be presented as QALYs per $1
million total budget [34]. A sensitivity analysis will explore
the extent of uncertainty in cost-effectiveness estimates
[48], as well as the impact of a probable cost reduction
for varenicline (once off-patent) on the cost-effectiveness
of cytisine versus varenicline. In addition, the incremental
cost-effectiveness ratios obtained by the method described
by Leaviss et al. will be calculated [20].
Ethical considerations
With the exception of biochemical verification of quitting,
trial participants are not seen and receive no reimburse-
ment for their time (although trial medication is free). A
two-step verbal consent process (documented on-line) is
used. Ethics approval was obtained on 22 November
2016 from the Southern Health and Disability Ethics Com-
mittee (16/STH/147). Approval for use of an unregistered
medicine (Tabex®) was obtained from the Standing
Committee on Therapeutic Trials on 3 April 2017
(16/SCOTT/93).
Governance
In addition to steering and management committees, a
Scientific and Dissemination Committee has been
established to provide advice about the trial design,
conduct and dissemination. Members have national and
international experience in tobacco control, varenicline,
cytisine, clinical safety, trial design and regulatory affairs.
As a Māori-focused study, a Kaitiaki (Māori governance
group) has been established to provide cultural advice
and support, direction on appropriate ways to recruit and
engage Māori into the trial and advice regarding data
analysis, interpretation and dissemination of the trial
findings. The Kaitiaki is supported by the NIHI Māori
research advisory group, which is endorsed by the Tumuaki
(Director) of the University of Auckland’s Faculty of
Medical and Health Sciences.
DISCUSSION
Recruitment started on 14 September 2017, with results
expected to be available late 2019.
Clinical Trial Registration
Trial Registration number: NCT02957786
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